Cullinan Shares Fall After Updated CLN-049 Data Show Lower Response Rates in ASH Abstracts
William Blair says updated ASH abstract data for Cullinan’s CLN-049 show lower response rates, sending shares down. Analyst keeps Outperform.
William Blair says updated ASH abstract data for Cullinan’s CLN-049 show lower response rates, sending shares down. Analyst keeps Outperform.
A missed Q3 RA readout, sector pressure, and high short interest hit CGEM. Cash still funds operations into 2029. Next data: November and December.
Cullinan Therapeutics’ CLN-978 T-cell engager showed deep B-cell depletion and clinical remissions in hard-to-treat lupus and rheumatoid arthritis patients after a single dose at EULAR 2026.
FDA gave orphan status to CLN-049 for AML. It uses T cells to attack cancer cells and is in early clinical trials.
UCB buys Candid Therapeutics for $2B+ to develop immune disease drug that may reset immune system; rivals’ stocks rise.
Gilead’s up to $2.2B acquisition of Ouro Medicines highlights strong potential for Cullinan Therapeutics’ velinotamig. Clear Street maintains Buy rating with $33 PT.